Considering that CEA reflects the tumor burden in mCRC6, we speculate that an increased CEA response may be a reflection of tumor shrinkage and a greater depth of response (DpR) in patients receiving an anti-EGFR mAb regimen than in those receiving an anti-VEGF mAb treatment. The gene discussed is EGFR; the disease is neoplasm.